XFOR
X4 Pharmaceuticals, Inc.3.7100
-0.0500-1.33%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
324.39MP/E (TTM)
-Basic EPS (TTM)
-8.92Dividend Yield
0%Recent Filings
10-K
FY2025 results
X4 Pharmaceuticals ended FY2025 with $253.0 million in cash, cash equivalents, and marketable securities after Q3/Q4 equity raises netting $226.6 million, funding operations into 2028 while prioritizing the 4WARD Phase 3 trial for mavorixafor in chronic neutropenia, targeting full enrollment by Q3 2026. Net product revenue from XOLREMDI reached $6.5 million annually, with Q4 at $2.3 million versus Q3's $1.6 million, plus $28.6 million from the Norgine license deal, but operating expenses fell to $122.0 million from $39.0 million in 2024 due to 65% headcount cuts via restructurings. Cash burn moderated to $85.6 million. Q4 accelerated trial site expansions to over 100 globally. Debt stands at $75.0 million under the Hercules facility, maturing July 2027. Clinical trial delays from patient identification challenges threaten quarterly momentum.
10-Q
Q3 FY2025 results
X4 Pharmaceuticals posted Q3 revenue of $1.8M, up 215% y/y from $0.6M, driven by $1.6M in U.S. product sales of XOLREMDI and $0.2M from the Norgine license deal, while YTD revenue soared to $32.5M from $28.3M in licensing fees plus $4.3M in product sales, a 2,796% y/y jump. Operating losses narrowed to $27.5M from $34.5M y/y, thanks to 30% and 50% workforce cuts that trimmed R&D to $17.3M and SG&A to $11.6M, though net loss widened to $29.8M from $36.7M due to a $0.7M warrant liability hit. Cash climbed to $122.2M with $81M from an August private placement, bolstering the $75M Hercules debt due 2027 at 11.4% effective rate; free cash flow not disclosed in the 10-Q. The January Norgine pact grants exclusive European rights for €28.5M upfront plus milestones up to €226M and mid-20s royalties. Yet clinical trial delays could stall mavorixafor's chronic neutropenia push.
8-K
X4 restructures, funds trial
X4 Pharmaceuticals restructured operations in Q3 2025, slashing its workforce by 50% to save $13 million annually while prioritizing the 4WARD Phase 3 trial for mavorixafor in chronic neutropenia over WHIM syndrome commercialization. Two financings raised $240.3 million, extending cash runway to end-2028 for trial completion and potential launch. Q3 net loss narrowed to $29.8 million from $36.7 million year-over-year. Restructuring sharpens focus amid trial risks.
8-K
X4 raises $145.6M in offering
X4 Pharmaceuticals priced a public offering on October 23, 2025, selling 45.86M common shares at $2.90 each and 700K pre-funded warrants at $2.899, with underwriters exercising their full 6.984M share option the next day. Net proceeds hit $145.6 million after fees, closing October 27. Cash bolsters runway amid biotech pressures.
8-K
X4 cuts workforce 50% for trial focus
X4 Pharmaceuticals announced a strategic restructuring on September 17, 2025, slashing its workforce by 50% to sharpen focus on the 4WARD Phase 3 trial for chronic neutropenia, yielding $13 million in annualized cost savings but incurring $3.3 million in severance charges. The move triggered exits of the COO, CCO, Chief Legal Officer, and CMO, with John Volpone stepping in as COO alongside his president role and Dr. Adam Craig overseeing clinical development. Restructuring sharpens execution. Yet actual savings hinge on unproven assumptions, risking operational hiccups.
CCCC
C4 Therapeutics, Inc.
2.26-0.17
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
RXRX
Recursion Pharmaceuticals, Inc.
4.20+0.00
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05
XLO
Xilio Therapeutics, Inc.
0.65+0.00
XNCR
Xencor, Inc.
16.55-0.24
XRTX
XORTX Therapeutics Inc.
0.59-0.01
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03